News

Biogen Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Biogen Inc. stock underperforms Wednesday when compared to competitors
Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...
EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...
Biogen reports EC grants marketing authorization for Leqembi
The European Commission has granted the amyloid-beta monoclonal antibody Leqembi Marketing Authorization in the European Union. Lecanemab is ...
Biogen (BIIB) Receives a Hold from Jefferies
Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...